 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During the last few years, data from different biological 
systems have revealed evidence for an age-related 
increase in the abundance of CypD, a peptidyl prolyl-
cis, trans-isomerase located in the mitochondrial matrix. 
Such an increase was reported in the short-lived aging 
model organism Podospora anserina [1,2] but also in 
rat gastrocnemius muscle and in brain tissue of mice 
and humans [2-3]. The enzyme is known to be involved 
in the regulation of the mitochondrial transition pore 
(mPTP) [4], a macromolecular mitochondrial protein 
complex the structure of which is still unsolved and 
controversial. The activity of CypD can be repressed by 
the cyclosporine A, a cyclic peptide used in human 
transplantation medicine or in treatment of Ullrich 
congenital dystrophy. In a recent aging study, a strong 
effect of CypD overexpression on mitochondrial 
ultrastucture structure and on aging was reported in P. 
anserina [5]. Overexpression strains were characterized 
by mitochondrial dysfunction and accelerated aging as 
the result of the induction of apoptosis. Treatment of 
CypD overexpressors was found to be effective in a 
reversion of the accelerated aging phenotype and it was 
suggested that cyclosporine A or other molecules 
affecting the function of CypD may be promising 
compounds for the development of anti-aging 
interventions by interfering into mitochondrial apoptotis 
pathways. In P. anserina apoptosis is the final pathway 
leading to death of this simple microbial aging model 
[6-9]. In contrast, in mammalian systems, it is rather 
represents a pathway relevant for development and 
protection against cancer. However, more and more data 
accumulate which also point to an important role of 
apoptosis in the  final life stage of mammals.  For  exemple, 
 
 
                                                       Commentary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
transgenic mice expressing a mutated gene of the 
mitochondrial DNA polymerase gamma, which, due to 
loss of the proof reading activity of this enzyme, 
express an accelerated aging phenotype with sarcopenia 
and an induction of apoptosis markers [10,11].  
 
In the last 2010 issue of AGING [12] Hafner et al. 
report the regulation of the mPTP of mice via 
deacetylation of CypD at lysine 166 by the NAD
+
-
dependent SIRT3 deacetylase. Mice lacking SIRT3 
display an accelerated aging phenotype correlated with 
increased mitochondrial swelling as the result of mPTP 
opening. Most remarkably, this phenotype is related to 
heart impairments and can be reverted by treatment with 
cyclosporine A. Sirt3 knockout mice are hypersensitive 
to heart stress, display cardiac hypertrophy and fibrosis. 
From their work the authors suggest that the phenotype 
of the mice is the result of an initial reduction of SIRT3 
activity leading to increases in susceptibility of mPTP 
formation. Subsequently this leads to impairments in 
NAD
+
 generation by mitochondria and, via a positive 
feedback cycle, to accelerated mitochondrial depolariza-
tion and destruction. In mammals, CypD thus appears to 
of relevance not only for skeletal muscle function but 
also in the heart connecting this pathway to one of the 
most important age-related death in humans, cardiac 
failure. Overall the data are an important piece of work 
towards the elucidation of the mechanistic details of 
mPTP regulation. Moreover, the work provides 
additional and very promising perspectives for the 
development of medical strategies to intervene into the 
part of the molecular network governing aging via 
Regulation of the mitochondrial transition pore: impact on 
mammalian aging 
 
Heinz D. Osiewacz      
 
Johann Wolfgang Goethe University, Faculty for Biosciences & Cluster of Excellence Molecular Complexes, 
Institute of Molecular Biosciences, 60438 Frankfurt, Germany 
 
Commentary on: Hafner AV et al. Regulation of the mPTP by SIRT3‐mediated deacetylation of CypD at lysine 166 suppresses 
age‐related cardiac hypertrophy. Aging. 2010; 12:914‐923. 
Received: 1/8/11; Accepted: 1/15/11; Published: 1/16/11 
Corresponding to:  osiewacz@bio.uni‐frankfurt.de 
© Osiewacz. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited 
 
 
www.impactaging.com AGING, January 2011, Vol. 3. No 1
 
 
www.impactaging.com                    10                                         AGING, January 2011, Vol.3 No.1
mitochondrial pathways involved in the control of 
apoptosis as they have been put forward earlier [7,13].  
 
REFERENCES 
 
1. Groebe K et al. Exp. Gerontol. 2007; 42, 887‐898. 
2. Du H et al. Nat. Med. 2008; 14: 1097‐1105.  
3. Marzetti E et al. Mech. Ageing Dev. 2008; 129: 542‐549. 
4. Kroemer G et al. Physiol. Rev. 2007; 87: 99‐163. 
5. Osiewacz HD. Mech. Ageing Dev. 2002; 123: 755‐764. 
6. Osiewacz HD et al. Ann. N. Y. Acad. Sci. 2010; 1197: 54‐66. 
7. Brust D et al. Aging Cell 2010; 9:761‐775. 
8. Hamann A et al. Mol Microbiol 2007; 65: 948‐958. 
9. Brust D et al. Curr. Genet. 2010; 56: 225‐235. 
10. Trifunovic A et al. Nature 2004; 429: 417‐423. 
11. Kujoth,G.C. et al. Science 2005; 309: 481‐484. 
12. Hafner AV et al. Aging 2010; 2: 914‐923. 
13. Osiewacz HD Aging 2010; 2: 357‐358. 
 
 
 
www.impactaging.com                    11                                         AGING, January 2011, Vol.3 No.1
